Advanced Psychedelic Training

Psilocybin and MDMA Therapy

Through world-class didactic content, in-person coaching, and the participation in the Health Canada approved clinical trial, students will be able to embody the roles of the psychedelic guide and the participant, allowing for the students to gain an understanding of the medicine from multiple perspectives.

Prerequisite Requirements

*The Introduction to Psychedelic-assisted Therapy Course is a prerequisite

About this program

The role of a psychedelic guide is unique, and we have developed this program based on an understanding of the uniqueness of this role. 

Supporting clients through psychedelic therapy protocols involves much more than just the session with psilocybin or other psychedelic medicine. Core competencies for therapists, preparation, integration and follow-up are all key components to seeing success for those embarking on this therapy process. Our training program is designed to address these important issues.

Lesson 1

History

Lesson 2

Access and Equity

Lesson 3

Ethics

Lesson 4

Pharmacology

Lesson 5

Therapeutic Modalities

Lesson 6

Role of a Psychedelic Guide

Lesson 7

Set

Lesson 8

Setting

Lesson 9

Integration

Lesson 10

Applications and Indications

Preregister Today

This course will be taught concurrent with the Phase II N500 clinical trial so students may cross participate on both the training and trial. As such, the Advanced Psychedelic Training Program start date will be available upon receiving approvals from Health Canada and Ethics Board to proceed which is expected to be in Fall or Winter 2022. Students must still meet the clinical trial requirements independent of the course to participate.

Frequently Asked Questions

Health Canada is opening the door slowly to patients to access psilocybin and MDMA for the purpose of therapy. This program will provide those who are qualified therapy providers, with an understanding of these medicines, and equip them with leading edge therapy protocols for the near future of psychedelic assisted therapy in Canada.

Therapy providers interested in how this program can allow them to participate in the coming Oregon legal framework for Psilocybin Services in 2023, please see Oregon Services.

While students are encouraged to participate in the clinical trial (as an important element of working with psychedelics is to have first-hand experience with the medicine), we understand that some students may have contraindications to psilocybin or do not meet the other inclusion/exclusion criteria of the trial, and are thus unable to partake in the experiential session.

Nonetheless, students will still be able to embody the role of the psychedelic guide and learn how to effectively guide others through their psychedelic journeys.

Yes, please contact us for more information on your eligibility. 

Scroll to Top